[{

    "fact":"Typically, MDMA is used only a few times a year.",
    "keywords":["dose", "patterns of use"],
    "references": [
      {
        "link": {
          "authors": ["Jan van Amsterdam.", "Gjalt-Jorn Ygram Peters.", "Ed Pennings.", "Tom Blickman.", "Kaj Hollemans.", "Joost J. Breeksema.", "Johannes Ramaekers.", "Cees Maris.", "Floor van Bakkum.", "Ton Nabben.", "Willem Scholten.", "Tjibbe Reitsma.", "Judith Noijen.", "Raoul Koning.", "Wim van den Brink."],
          "title": "Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis (MD-MCDA)",
          "year": 2020,
          "uri": "https://files.de-1.osf.io/v1/resources/txy5z/providers/osfstorage/5fa90f03d1894f014a68acfb?action=download&direct&version=2"
        },
        "excerpt": "Typically, ecstasy is used only a few times a year (Nabben et al. 2018; Szigeti et al. 2018; van Laar and van Ooyen-Houben 2017).",
        "keywords": ["dose", "patterns of use"],
        "referenced_links": [
          {
            "authors":["Nabben T.", "Luijk SJ.", "Korf DJ."],
            "title": "Trends in alcohol, tabak en drugs bij jonge Amsterdammers. Amsterdam: Rozenberg Publishers.",
            "year": 2018,
            "uri": "http://www.bonger.nl/PDF/Antenne%20Amsterdam%202017.pdf"
          },
          {
            "authors":["Szigeti B.", "Winstock AR.", "Erritzoe D.", "et al."],
            "title": "Are ecstasy induced serotonergic alterations overestimated for the majority of users? J. Psychopharmacol. 32: 741-748.",
            "year": 2018,
            "uri": "https://pubmed.ncbi.nlm.nih.gov/29733742/"
          },
          {
            "authors":["van Laar MW.", "van Ooyen-Houben MMJ."],
            "title": "Nationale Drugs Monitor Jaarbericht 2016. Utrecht: Trimbos Instituut.",
            "year": 2017,
            "uri": "https://www.trimbos.nl/docs/3fdeab39- f34e-4aa0-97af-5dbf111c05a0.pdf"
          }
        ]

      }

    ]

  },

  {

    "fact":"In the Netherlands, MDMA was scheduled on List I of the Opium Act because of concerns about large-scale trade and production of ecstasy. ",
    "keywords":["history" ,"Netherlands", "international classification"],
    "references": [
      {
        "link": {
          "authors": ["Jan van Amsterdam.", "Gjalt-Jorn Ygram Peters.", "Ed Pennings.", "Tom Blickman.", "Kaj Hollemans.", "Joost J. Breeksema.", "Johannes Ramaekers.", "Cees Maris.", "Floor van Bakkum.", "Ton Nabben.", "Willem Scholten.", "Tjibbe Reitsma.", "Judith Noijen.", "Raoul Koning.", "Wim van den Brink."],
          "title": "Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis (MD-MCDA)",
          "year": 2020,
          "uri": "https://files.de-1.osf.io/v1/resources/txy5z/providers/osfstorage/5fa90f03d1894f014a68acfb?action=download&direct&version=2"
        },

        "excerpt": "In the Netherlands, MDMA was scheduled on List I of the Opium Act because of concerns about large-scale trade and production of ecstasy, i.e., not because of emerging health concerns. ",
        "keywords": ["history" ,"Netherlands", "international classification"],
        "referenced_links": [
        ]

      }

    ]

  },

  {

    "fact":"The dependence liability of MDMA is low and its use is generally less harmful than amphetamine, cocaine and heroin.",

    "keywords":["dependence", "risk of harm"],

    "references": [

      {

        "link": {

          "authors": ["Jan van Amsterdam.", "Gjalt-Jorn Ygram Peters.", "Ed Pennings.", "Tom Blickman.", "Kaj Hollemans.", "Joost J. Breeksema.", "Johannes Ramaekers.", "Cees Maris.", "Floor van Bakkum.", "Ton Nabben.", "Willem Scholten.", "Tjibbe Reitsma.", "Judith Noijen.", "Raoul Koning.", "Wim van den Brink."],

          "title": "Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis (MD-MCDA)",

          "year": 2020,

          "uri": "https://files.de-1.osf.io/v1/resources/txy5z/providers/osfstorage/5fa90f03d1894f014a68acfb?action=download&direct&version=2"

        },
        "excerpt": "The dependence liability of MDMA is low and its use is generally less harmful than other List I drugs, e.g. amphetamine, cocaine and heroin (Nutt et al. 2010; van Amsterdam et al. 2010).",
        "keywords": ["dependence", "risk of harm"],
        "referenced_links": [
          {
            "authors":["Nutt DJ.", "King LA.", "Phillips LD."],
            "title": "Drug harms in the UK: a multicriteria decision analysis. Lancet 376: 1558-1565.",
            "year": 2010,
            "uri": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61462-6/fulltext"
          },
          {

            "authors":["van Amsterdam J.", "Opperhuizen A.", "Koeter M.", "et al."],

            "title": "Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur. Addict. Res. 16: 202- 207.",

            "year": 2010,

            "uri": "https://pubmed.ncbi.nlm.nih.gov/20606445/"

          }

        ]

      }

    ]

  },

  {

    "fact":"Dutch policy makers and influencers are currently considering a revision of the national MDMA policy.",

    "keywords":["roadmap", "policy"],

    "references": [

      {

        "link": {

          "authors": ["Jan van Amsterdam.", "Gjalt-Jorn Ygram Peters.", "Ed Pennings.", "Tom Blickman.", "Kaj Hollemans.", "Joost J. Breeksema.", "Johannes Ramaekers.", "Cees Maris.", "Floor van Bakkum.", "Ton Nabben.", "Willem Scholten.", "Tjibbe Reitsma.", "Judith Noijen.", "Raoul Koning.", "Wim van den Brink."],

          "title": "Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis (MD-MCDA)",

          "year": 2020,

          "uri": "https://files.de-1.osf.io/v1/resources/txy5z/providers/osfstorage/5fa90f03d1894f014a68acfb?action=download&direct&version=2"

        },


        "excerpt": "Faced with increasing public awareness of a possibly inappropriate scheduling of MDMA and the growing concerns about MDMA-related crime, many Dutch policy makers and influencers are currently considering a revision of the national MDMA policy.",

        "keywords": ["roadmap", "policy"],

        "referenced_links": [


        ]

      }

    ]

  },

  {

    "fact":"Despite a slight increase in prevalence of use, an increase in the level of MDMA dependence is not expected mainly because of the low dependence potential of MDMA",

    "keywords":["dependence", "roadmap", "effects of legalisation"],

    "references": [

      {

        "link": {

          "authors": ["Jan van Amsterdam.", "Gjalt-Jorn Ygram Peters.", "Ed Pennings.", "Tom Blickman.", "Kaj Hollemans.", "Joost J. Breeksema.", "Johannes Ramaekers.", "Cees Maris.", "Floor van Bakkum.", "Ton Nabben.", "Willem Scholten.", "Tjibbe Reitsma.", "Judith Noijen.", "Raoul Koning.", "Wim van den Brink."],

          "title": "Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis (MD-MCDA)",

          "year": 2020,

          "uri": "https://files.de-1.osf.io/v1/resources/txy5z/providers/osfstorage/5fa90f03d1894f014a68acfb?action=download&direct&version=2"

        },

        "page":16,

        "excerpt": "Despite a slight increase in prevalence of use, an increase in the level of ecstasy dependence is not expected mainly because of the low dependence potential of ecstasy (Alderliefste and Damen 2018; EMCDDA 2019; van Laar et al. 2019). ",

        "keywords": ["dependence", "roadmap", "effects of legalisation"],

        "referenced_links": [

          {

            "authors":["Alderliefste GJ.", "Damen J." (2018). "],

            "title": "Partydrugsgerelateerde klachten. DOI:10.1007/s12445- 018-0285-y. Huisarts Wetenschap 61: 1-4.",

            "year": 2018,

            "uri": "https://www.henw.org/system/files/download/10.1007%252Fs12445-018-0285-y.pdf"

          },
          {

            "authors":["EMCDDA."],

            "title": "European Monitoring Center for Drugs and Drug Addiction (EMCDDA). United Kingdom: Country drug report 2019. Lisbon, Portugal.",

            "year": 2019,

            "uri": "http://www.emcdda.europa.eu/countries/drug-reports/2019/united-kingdom/key- statistics_en"

          },
          {

            "authors":["van Laar MW.", "van Gestel B.", "Cruts AAN.", "et al."],

            "title": "Nationale Drug Monitor. Jaarbericht 2018. Trimbos Instituut, Utrecht, The Netherlands.",

            "year": 2019,

            "uri": "https://www.trimbos.nl/aanbod/webwinkel/product/af1643-jaarbericht-nationale- drug-monitor-2018"

          }


        ]

      }

    ]

  },

  {

    "fact":"Optimal model includes the ‘inter se’ option for treaty modification",

    "keywords":["roadmap","policy"],

    "references": [

      {

        "link": {

          "authors": ["Jan van Amsterdam.", "Gjalt-Jorn Ygram Peters.", "Ed Pennings.", "Tom Blickman.", "Kaj Hollemans.", "Joost J. Breeksema.", "Johannes Ramaekers.", "Cees Maris.", "Floor van Bakkum.", "Ton Nabben.", "Willem Scholten.", "Tjibbe Reitsma.", "Judith Noijen.", "Raoul Koning.", "Wim van den Brink."],

          "title": "Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis (MD-MCDA)",

          "year": 2020,

          "uri": "https://files.de-1.osf.io/v1/resources/txy5z/providers/osfstorage/5fa90f03d1894f014a68acfb?action=download&direct&version=2"

        },

        "page":16,

        "excerpt": "The optimal model includes the ‘inter se’ option for treaty modification, as provided by Article 41 of the 1969 Vienna Convention on the Law of Treaties. Inter se modification is a procedure specifically designed to find a balance between treaty regime stability and the need for change in absence of consensus, whereby a group of two or more like-minded states could reach agreements among themselves that permit the production, trade, and consumption of scheduled substances for non-medical and non-scientific purposes, while minimizing the impact on other states and on the goals of the drug conventions (Boister and Jelsma 2018). Following international consultations and negotiations through the inter se option, neighbouring countries may implement comparable legislation. Legal producers in the Netherlands can then supply high quality MDMA-products to consumers in those countries (and vice versa). The more countries adapting such legislation, the more effectively MDMA- related organized crime is side-lined.",

        "keywords": ["roadmap","policy"],

        "referenced_links": [

          {

            "authors":["Boister and Jelsma 2018"],

            "title": "",

            "year": 2018,

            "uri": ""

          },
            

        ]

      }

    ]

  },
  {
    "fact": "",
    "keywords":[""],
    "references": [
      {
        "link": {
          "authors": ["Jan van Amsterdam.", "Gjalt-Jorn Ygram Peters.", "Ed Pennings.", "Tom Blickman.", "Kaj Hollemans.", "Joost J. Breeksema.", "Johannes Ramaekers.", "Cees Maris.", "Floor van Bakkum.", "Ton Nabben.", "Willem Scholten.", "Tjibbe Reitsma.", "Judith Noijen.", "Raoul Koning.", "Wim van den Brink."],
          "title": "Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis (MD-MCDA)",
          "year": 2020,
          "uri": "https://files.de-1.osf.io/v1/resources/txy5z/providers/osfstorage/5fa90f03d1894f014a68acfb?action=download&direct&version=2"
        },
        "excerpt": "",
        "keywords": [""],
        "referenced_links": [
          {
            "authors":[""],
            "title": "",
            "year": 9999,
            "uri": ""
          }
        ]

      }
    ]
  }
]
